-
-
-
-
-
-
-
Quince Therapeutics settles $16.4 million debt for $5.5 million payment
-
-
-
-
-
-
-
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
-
-
-
-
-
-
-
Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value
-
-
-
-
-
-
-
Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital
-
-
-
-
-
-
-
Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name
1,160,493 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

